Oncobiologics (NASDAQ:OTLK) Price Target Raised to $1.60

Oncobiologics (NASDAQ:OTLK) had its price objective raised by HC Wainwright from $0.50 to $1.60 in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a neutral rating on the stock. HC Wainwright also issued estimates for Oncobiologics’ Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.01) EPS, Q2 2027 earnings at ($0.01) EPS, Q3 2027 earnings at ($0.01) EPS, Q4 2027 earnings at $0.00 EPS, FY2027 earnings at ($0.03) EPS, FY2028 earnings at $0.09 EPS, FY2029 earnings at $0.15 EPS and FY2030 earnings at $0.32 EPS.

Several other research firms have also commented on OTLK. Weiss Ratings raised shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. BTIG Research raised shares of Oncobiologics from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a research report on Monday. Wall Street Zen cut shares of Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Ascendiant Capital Markets raised their target price on shares of Oncobiologics from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Oncobiologics has an average rating of “Hold” and an average price target of $4.65.

Oncobiologics Price Performance

Shares of NASDAQ OTLK opened at $1.00 on Monday. Oncobiologics has a 1-year low of $0.16 and a 1-year high of $3.39. The business has a fifty day moving average price of $1.22 and a 200 day moving average price of $0.66. The stock has a market capitalization of $148.59 million, a P/E ratio of -0.85 and a beta of 0.77.

Oncobiologics (NASDAQ:OTLK) last posted its earnings results on Friday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $4.39 million. As a group, equities research analysts anticipate that Oncobiologics will post -0.49 earnings per share for the current fiscal year.

Insider Activity

In other Oncobiologics news, Director Ghiath M. Sukhtian purchased 8,539,709 shares of the stock in a transaction on Thursday, May 28th. The stock was acquired at an average price of $0.59 per share, with a total value of $5,038,428.31. Following the completion of the acquisition, the director owned 22,092,068 shares in the company, valued at $13,034,320.12. The trade was a 63.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Faisal Ghiath Sukhtian purchased 95,398 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were acquired at an average price of $1.05 per share, for a total transaction of $100,167.90. Following the purchase, the director directly owned 220,972 shares of the company’s stock, valued at approximately $232,020.60. The trade was a 75.97% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 8,664,107 shares of company stock valued at $5,162,666. Corporate insiders own 1.80% of the company’s stock.

Institutional Trading of Oncobiologics

Several large investors have recently bought and sold shares of OTLK. Russell Investments Group Ltd. increased its stake in Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after purchasing an additional 21,941 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after buying an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after buying an additional 44,063 shares during the period. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Key Headlines Impacting Oncobiologics

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Director Faisal Ghiath Sukhtian bought 95,398 shares at an average price of $1.05, investing approximately $100,168. The purchase increased his direct ownership by nearly 76% to 220,972 shares, a potential signal of insider confidence. SEC insider transaction filing
• Positive Sentiment: BTIG Research upgraded OTLK to “Buy,” providing a stronger bullish view than the existing neutral coverage. BTIG Research upgrades Oncobiologics
• Positive Sentiment: HC Wainwright substantially improved its forecasts for 2027, raising full-year EPS expectations to a loss of $0.03 from a loss of $0.21. It also projects a return to profitability in 2028, with EPS of $0.09, followed by $0.15 in 2029 and $0.32 in 2030. The firm maintains a $1.60 price target.
• Neutral Sentiment: HC Wainwright raised estimates for several 2026–2027 quarters, but still rates OTLK “Neutral.” Its FY2026 EPS forecast was reduced to a loss of $0.47 from $0.42, indicating that near-term profitability remains uncertain.
• Negative Sentiment: A separate report on LYTENAVA—identified in the article as an Outlook Therapeutics program—cited significant cash constraints and the need for funding or a partnership before a U.S. launch. Although the therapy has FDA and European approval, competition in the anti-VEGF market could make commercialization difficult. Caution on LYTENAVA approval and cash needs

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.